Insights
Insights From Our Experts
Articles
Launch Sequencing and Market Prioritization in an Evolving Global Market
The world is facing a multitude of governing and legislative changes that will directly affect pharmaceutical pricing in the coming years, with many of these changes exacerbated by the pandemic. As countries become increasingly interconnected, decisions…
Aligning Net Pricing with Patient Outcomes – Removing Barriers to Value-Based Contracting
While value-based contracting has long been heralded as a way to ensure the cost of life-changing and life-saving medicines are aligned with patient outcomes, the complexity in their implementation has limited adoption to just a few…
30 Years of Insights: A look into the future of research and insights and the need for connectivity to navigate market access challenges
Thirty years ago, the industry faced a new problem: Pharmacy benefit managers were wreaking havoc by negotiating and controlling drug spending with pharmaceutical companies and pharmacies. This resulted in a significant behind-the-scenes impact in determining total…
Rx-to-OTC Switch Tips: Identifying the Right Timing, Conditions, and Approach for Rx-to-OTC Conversion
Exploring the idea of converting a prescription (Rx) drug to an over-the-counter (OTC) product can be a useful part of life cycle management and loss of exclusivity planning. However, while an Rx-to-OTC switch could provide significant…
Options and Insights for Successful Development and Launch
Pharma Sponsored Digital Health Solutions and Digital Therapeutics (DTx): Options and Insights for Successful Development and Launch Listen to EVERSANA’s Scott Snyder and Jim O’Donoghue of S3 Connected Health in this recorded webinar as they share insights on the driving…
Considering Commercial Success During Clinical Development: Maintaining a Global Perspective
Posted by
Melissa Thompson, B.Sc., MBA , Mike Ryan , Adam Hardy , Ari Mendell, MSc, PhD , Joshua Gauci , Nicole Hengst on December 6, 202112/6/21
Although commercial success is the ultimate goal of pharmaceutical research and development (R&D), many new treatments do not meet expectations and fail to achieve broad global reimbursement after initial regulatory approval., This causes therapies to underperform across international markets…
Client Story: An Ode to EVERSANA
At EVERSANA, putting our clients and patients first is at the forefront of everything we do. Recently, when EVERSANA ENGAGE’s Bausch & Lomb (B&L) team closed out their last event of their speaker series, they didn’t just…
WEBINAR: Reimagining the Patient Journey for CGTs: Informing, Engaging and Empowering the Patient Population
Posted by
Seth Gordon on December 2, 202112/2/21
Cell and gene therapies (CGTs) hold great life-saving and therapeutic advancement potential, but their complexity requires careful approach–starting with engaging and educating patient communities earlier. While the patient’s voice should be a guiding force throughout the…
BLOG: Segmenting Health Systems
Posted by
Dr. Richard Stefanacci on December 1, 202112/1/21
The COVID-19 pandemic has separated health systems based on the impact of the pandemic on their staff, operations and finances. While many health systems have struggled in these areas, some have truly succeeded. This means that…
Breaking News: Updates on Digital Medicine Coding and Payment
Over the past several months, we have been following the activities of the American Medical Association (AMA) and the Centers for Medicare and Medicaid Services (CMS) regarding coding and payment, respectively, for digital medicine products. Both…